S.Biomedics Co., Ltd. (KOSDAQ:304360)

South Korea flag South Korea · Delayed Price · Currency is KRW
38,150
-200 (-0.52%)
At close: Feb 27, 2026
Market Cap472.49B +89.3%
Revenue (ttm)16.96B +30.3%
Net Income-9.58B
EPS-810.50
Shares Out12.39M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume77,148
Average Volume87,083
Open38,250
Previous Close38,350
Day's Range37,800 - 39,200
52-Week Range17,930 - 42,600
Beta1.26
RSI60.70
Earnings DateMar 20, 2026

About S.Biomedics

S.Biomedics CO., LTD., a biopharmaceutical company, engages in the research and development of stem cells therapy products. Its product pipeline comprises TED-N, which is in phase 1/2a clinical development for the treatment of subacute spinal cord injury; TED-A9, which is in phase 1/2a clinical development for the treatment of parkinson’s disease; FECS-Ad, which is 1/2a for the treatment of critical limb ischemia; FECS-DF, which is in phase 1/2 clinical development for the treatment of crows feet; TED-R for the treatment of macular degeneration... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2005
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 304360
Full Company Profile

Financial Performance

In 2024, S.Biomedics's revenue was 13.73 billion, an increase of 4.77% compared to the previous year's 13.11 billion. Losses were -6.69 billion, -35.17% less than in 2023.

Financial Statements